Renexxion Ireland Innovation There is a large unmet medical need for patients with disorders of gastrointestinal motility. Naronapride, a late-development stage, Phase-3 ready, oral gastro-prokinetic, 5-HT4 agonist has shown efficacy in a wide range of these disorders. It is estimated that at least 16% of people worldwide suffer from GI-related disorders. Currently approved therapies do not completely address this high therapeutic need. In some cases, there are no approved therapies. Naronapride has the potential to address the major GI indications associated with dysmotility including chronic idiopathic constipation (CIC), irritable bowel syndrome - constipation type (IBSc), functional dyspepsia (FD), gastroparesis (GP), and gastro-esophageal reflux disease (GERD), in particular PPI-resistant GERD where chronic oral treatments are required. Naronapride may also address unmet therapeutic needs in smaller GI-related indications, both chronic and acute. These include Enteral Feeding Intolerance (EFI), acute GP, short bowel syndrome (SBS), and post-operative ileus (POI).
View Top Employees from Renexxion Ireland LtdWebsite | http://www.rnexltd.ie |
Revenue | $6 million |
Employees | 12 (7 on RocketReach) |
Founded | 2014 |
Phone | (650) 924-9895 |
Fax | (415) 449-3581 |
Technologies |
JavaScript,
HTML,
Google Analytics
+9 more
(view full list)
|
Industry | Pharmaceutical Manufacturing, Drug Manufacturing & Research, Pharmaceuticals, Healthcare |
SIC | SIC Code 283 Companies, SIC Code 28 Companies |
NAICS | NAICS Code 32541 Companies, NAICS Code 3254 Companies, NAICS Code 32 Companies, NAICS Code 325 Companies |
Looking for a particular Renexxion Ireland Ltd employee's phone or email?
The Renexxion Ireland Ltd annual revenue was $6 million in 2024.
Peter Milner is the Chief Executive Officer and Chairman of Renexxion Ireland Ltd.
7 people are employed at Renexxion Ireland Ltd.
The NAICS codes for Renexxion Ireland Ltd are [32541, 3254, 32, 325].
The SIC codes for Renexxion Ireland Ltd are [283, 28].